Profound Medical Corp.
NASDAQ:PROF · NASDAQ Capital Market
+$0.27 today
Vol 0.09M · Avg 0.12M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PROF · Revenue to Net Income
Key Ratios
Analysis
$18.9M of revenue converted into -$39.2M of net income for the selected period. Gross margin is 71.5% and net margin is -282.4%, showing how much revenue survives after costs and taxes. EPS is $-1.25, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.4M +61.1% | $10.2M +41.2% | $7.2M +7.8% | $6.7M -2.8% | $6.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $4.8M +38.0% | $3.5M +23.1% | $2.8M -23.0% | $3.7M -6.7% | $3.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $11.6M +73.0% | $6.7M +52.9% | $4.4M +45.1% | $3.0M +2.3% | $3.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 70.8% +4.9pp | 65.9% +5.0pp | 60.9% +15.7pp | 45.2% +2.3pp | 43.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $21.0M +29.8% | $16.2M +12.3% | $14.4M -2.1% | $14.7M -3.8% | $15.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $32.6M +48.1% | $22.0M +18.3% | $18.6M +3.8% | $17.9M -0.2% | $18.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $53.6M +40.3% | $38.2M +15.7% | $33.0M -6.1% | $35.1M +5.7% | $33.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $569.8K -36.1% | $891.1K -22.2% | $1.1M -28.6% | $1.6M -14.6% | $1.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$41.4M -61.8% | -$25.6M +4.4% | -$26.8M -0.7% | -$26.6M +7.1% | -$28.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -252.8% -1.1pp | -251.7% +120.3pp | -372.0% +26.2pp | -398.2% +18.6pp | -416.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$42.0M -33.4% | -$31.5M -10.0% | -$28.6M +10.9% | -$32.1M -6.1% | -$30.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -256.3% +53.3pp | -309.6% +87.9pp | -397.5% +83.4pp | -480.9% -40.1pp | -440.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1M -20.4% | $1.4M -16.7% | $1.6M +56.4% | $1.0M +416.6% | $203.2K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $770.0K +360.8% | $167.1K +151.6% | $66.4K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.1M -121.7% | $5.0M +6263.2% | -$81.0K -102.2% | $3.7M +1335.6% | -$303.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$43.1M -62.6% | -$26.5M +7.7% | -$28.7M -1.1% | -$28.4M +7.2% | -$30.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -262.9% -2.4pp | -260.5% +138.2pp | -398.6% +26.2pp | -424.8% +20.3pp | -445.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $256.4K +13574.0% | -$1.9K +98.5% | -$128.0K -144.6% | $287.0K +173.3% | $105.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$43.3M -63.6% | -$26.5M +7.3% | -$28.6M +0.3% | -$28.7M +6.6% | -$30.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -264.4% -4.0pp | -260.4% +136.4pp | -396.8% +32.3pp | -429.1% +17.5pp | -446.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -33.6% | -$1 +20.7% | -$1 +2.2% | -$1 +8.0% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -33.6% | -$1 +20.7% | -$1 +2.2% | -$1 +8.0% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $30.2M +22.1% | $24.8M +16.9% | $21.2M +1.7% | $20.8M +1.8% | $20.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $30.2M +22.1% | $24.8M +16.9% | $21.2M +1.7% | $20.8M +1.8% | $20.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$348.20M
Prenetics Global Limited
NASDAQ:PRE
$343.75M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$258.44M
Perspective Therapeutics, Inc.
AMEX:CATX
$232.14M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$147.66M
MaxCyte, Inc.
NASDAQ:MXCT
$125.90M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$119.35M
Owlet, Inc.
NYSE:OWLT
$90.11M
Neuronetics, Inc.
NASDAQ:STIM
$84.61M
LENSAR, Inc.
NASDAQ:LNSR
$71.05M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PROF generate?
Profound Medical Corp. (PROF) reported $16.38M of revenue in fiscal 2025.
Is PROF profitable?
Profound Medical Corp. (PROF) reported -$43,315,210.00 of net income, with a net margin of -264.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.